Back to search results

USCOM for Fetal Growth Restriction (FGR)

This study is looking at how a device called USCOM can be used in pregnant patients who have recently been diagnosed with Fetal Growth Restriction (FGR). FGR means the baby is not growing as expected. The USCOM device measures how much blood is being pumped in and out of the heart. Researchers want to see if this measurement, called systemic vascular resistance, can help them understand the heart's function during pregnancy in these cases. You might be able to join if you are pregnant, at least 18 years old, and have a new diagnosis of FGR in your third trimester (after 27 weeks and 6 days of pregnancy). The study is currently unclear on its recruitment status and plans to enroll 100 participants.

Study design
This is an observational study, meaning researchers will be watching and collecting information. It plans to include 100 participants.
What's involved
You would have your systemic vascular resistance measured using the USCOM device every 2-4 weeks during your prenatal ultrasounds, until the end of your pregnancy.
Compensation
Not stated in the trial record.
Follow-up
Measurements will be taken until the end of your pregnancy.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06343051

USCOM in Newly Diagnosed FGR Cases

Completed
Not specifiedAges 18+Observational
Icahn School of Medicine at Mount Sinai
~13 participants
Updated 2026-08-24 on ClinicalTrials.gov
What's tested:USCOM

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Systemic vascular resistance obtained from USCOM
Measured over every 2-4 weeks at time of prenatal ultrasound, until the end of pregnancy

Conditions

Fetal Growth Restriction
USCOM

Explore related trials

Fetal growth restriction

Where it's being run

1 sites across 1 states
New York1

Study leadership

  • Nicola F Tavella, MPH · STUDY_DIRECTOR · Icahn School of Medicine at Mount Sinai
  • Rachel J Meislin, MD · PRINCIPAL_INVESTIGATOR · Icahn School of Medicine at Mount Sinai

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Pregnant patients with a new diagnosis of fetal growth restriction (estimated fetal weight \<10th percentile or abdominal circumference \<10th percentile) in the third trimester (gestational age \>27w6d)

Exclusion

Multiple gestation
Fetal anomalies
Gestational diabetes or pregestational diabetes.

What this trial measures

  • Systemic vascular resistance obtained from USCOMevery 2-4 weeks at time of prenatal ultrasound, until the end of pregnancy

    Cardiac output related to systemic vascular resistance (SVR) obtained from the USCOM device. SVR is an indicator of general resistance experienced within the circulatory system and is correlated with an array of cardiac related adverse health outcomes. The USCOM device uses noninvasive ultrasonographic technology to determine SVR at the time of prenatal ultrasound.